| Daniel Sova, MD | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 502-2447 | |
| Not Available |
| Full Name | Daniel Sova |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 10 Years |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104230499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | D85112 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kennedy Krieger Associates | 1759280597 | 54 |
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
A drug that is already being tested as an anticancer agent, especially in lymphoma, may also reduce the kidney disease that is a result of systemic lupus, according to a researcher at Wake Forest University Baptist Medical Center.
In a recent study, breast feeding during infancy was associated with a lower risk of lower limb fractures when children reached young adulthood, while maternal smoking was associated with a higher risk of upper limb fractures.
A new book published today aims to help children stay hopeful and positive during the COVID-19 pandemic. The story is a sequel to 'My Hero is You: how kids can fight COVID-19!', published in April 2020.
Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.
Pathological changes typical of Alzheimer's disease were significantly reduced in mice by blockade of an immune system transmitter. A research team from Charité - Universitätsmedizin Berlin and the University of Zurich has just published a new therapeutic approach in fighting Alzheimer's disease in the current issue of Nature Medicine. This approach promises potential in prevention, as well as in cases where the disease has already set in.
› Verified 3 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
A drug that is already being tested as an anticancer agent, especially in lymphoma, may also reduce the kidney disease that is a result of systemic lupus, according to a researcher at Wake Forest University Baptist Medical Center.
In a recent study, breast feeding during infancy was associated with a lower risk of lower limb fractures when children reached young adulthood, while maternal smoking was associated with a higher risk of upper limb fractures.
A new book published today aims to help children stay hopeful and positive during the COVID-19 pandemic. The story is a sequel to 'My Hero is You: how kids can fight COVID-19!', published in April 2020.
Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.
Pathological changes typical of Alzheimer's disease were significantly reduced in mice by blockade of an immune system transmitter. A research team from Charité - Universitätsmedizin Berlin and the University of Zurich has just published a new therapeutic approach in fighting Alzheimer's disease in the current issue of Nature Medicine. This approach promises potential in prevention, as well as in cases where the disease has already set in.
› Verified 3 days ago
| Entity Name | Kennedy Krieger Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871515783 PECOS PAC ID: 1759280597 Enrollment ID: O20031231000300 |
News Archive
A drug that is already being tested as an anticancer agent, especially in lymphoma, may also reduce the kidney disease that is a result of systemic lupus, according to a researcher at Wake Forest University Baptist Medical Center.
In a recent study, breast feeding during infancy was associated with a lower risk of lower limb fractures when children reached young adulthood, while maternal smoking was associated with a higher risk of upper limb fractures.
A new book published today aims to help children stay hopeful and positive during the COVID-19 pandemic. The story is a sequel to 'My Hero is You: how kids can fight COVID-19!', published in April 2020.
Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.
Pathological changes typical of Alzheimer's disease were significantly reduced in mice by blockade of an immune system transmitter. A research team from Charité - Universitätsmedizin Berlin and the University of Zurich has just published a new therapeutic approach in fighting Alzheimer's disease in the current issue of Nature Medicine. This approach promises potential in prevention, as well as in cases where the disease has already set in.
› Verified 3 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1972150126 PECOS PAC ID: 8921903147 Enrollment ID: O20191217001657 |
News Archive
A drug that is already being tested as an anticancer agent, especially in lymphoma, may also reduce the kidney disease that is a result of systemic lupus, according to a researcher at Wake Forest University Baptist Medical Center.
In a recent study, breast feeding during infancy was associated with a lower risk of lower limb fractures when children reached young adulthood, while maternal smoking was associated with a higher risk of upper limb fractures.
A new book published today aims to help children stay hopeful and positive during the COVID-19 pandemic. The story is a sequel to 'My Hero is You: how kids can fight COVID-19!', published in April 2020.
Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.
Pathological changes typical of Alzheimer's disease were significantly reduced in mice by blockade of an immune system transmitter. A research team from Charité - Universitätsmedizin Berlin and the University of Zurich has just published a new therapeutic approach in fighting Alzheimer's disease in the current issue of Nature Medicine. This approach promises potential in prevention, as well as in cases where the disease has already set in.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Sova, MD 9910 Franklin Square Dr Ste 2110, Baltimore, MD 21236-4902 Ph: (410) 933-6423 | Daniel Sova, MD 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 502-2447 |
News Archive
A drug that is already being tested as an anticancer agent, especially in lymphoma, may also reduce the kidney disease that is a result of systemic lupus, according to a researcher at Wake Forest University Baptist Medical Center.
In a recent study, breast feeding during infancy was associated with a lower risk of lower limb fractures when children reached young adulthood, while maternal smoking was associated with a higher risk of upper limb fractures.
A new book published today aims to help children stay hopeful and positive during the COVID-19 pandemic. The story is a sequel to 'My Hero is You: how kids can fight COVID-19!', published in April 2020.
Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.
Pathological changes typical of Alzheimer's disease were significantly reduced in mice by blockade of an immune system transmitter. A research team from Charité - Universitätsmedizin Berlin and the University of Zurich has just published a new therapeutic approach in fighting Alzheimer's disease in the current issue of Nature Medicine. This approach promises potential in prevention, as well as in cases where the disease has already set in.
› Verified 3 days ago
Robert S Mayer, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-532-4701 | |
Nia C Wallace Ward, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 707 N Broadway, Kennedy Krieger Institute, Baltimore, MD 21205 Phone: 443-923-9200 Fax: 443-923-9405 | |
Susan Miller, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7500 Security Blvd, Mailstop: C1-09-06, Baltimore, MD 21244 Phone: 410-786-2118 | |
Christine Yunjae Wang, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2401 W Belvedere Ave, Baltimore, MD 21215 Phone: 410-601-9000 | |
Jason P Brokaw, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2700 Quarry Lake Drive, Suite 300, Baltimore, MD 21209 Phone: 410-377-8900 Fax: 410-377-3156 | |
Pablo Ariel Celnik, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-532-4701 | |
Behnam Jafarpour, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3421 Benson Ave, Suite 210, Baltimore, MD 21227 Phone: 443-693-7246 |